Auxilium Announces Results From Phase III Trial That Show AA4500 Successful In Treating Dupuytren's Contracture

Wed, 21 Feb 2007 02:00 PM EST

... Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced the positive final results of an early Phase III study of its lead development product AA4500 in the treatment of Dupuytren's contracture, a disabling and recurring hand condition in which the joints contract, impairing patients' ability to straighten and move their fingers. [click link for full article] ...